Ketoconazol Korhispana

Quick links

Choose a section

Quick links to important sections

Advertisements

Ketoconazol Korhispana

Advertisements
Advertisements

Overview of Ketoconazol Korhispana

What is Ketoconazol Korhispana?

Ketoconazol Korhispana is a medicinal product containing ketoconazole, an active pharmaceutical ingredient classified as an antifungal agent. It belongs to a group of drugs known as imidazole derivatives. This medication is primarily used to treat infections caused by fungi and yeasts.

Mechanism of Action

The active substance works by interfering with the synthesis of ergosterol, which is a vital component of the fungal cell membrane. By inhibiting the production of this substance, the medication disrupts the integrity of the cell wall, which prevents the fungus from growing and replicating, or leads to the destruction of the fungal cell.

Therapeutic Applications

Ketoconazol Korhispana is formulated for various types of fungal infections. Depending on the specific presentation of the medication, it may be used for:

  • Skin Infections: Treatment of localized fungal infections affecting the trunk, groin, hands, or feet.
  • Scalp Conditions: Management of conditions such as seborrheic dermatitis and pityriasis capitis (dandruff), which are often associated with the presence of the yeast Malassezia.
  • Cutaneous Candidiasis: Treatment of skin infections caused by Candida species.
  • Pityriasis Versicolor: A common skin condition characterized by small, discolored patches caused by a fungal overgrowth.

Formulations

This medication is typically available in topical forms, such as creams or gels, designed to act directly on the affected area of the skin or scalp. These formulations allow the active ingredient to reach the site of infection with minimal systemic absorption.

Regulatory References

  1. MedlinePlus drug profile
Advertisements

What side effects are possible with Ketoconazol Korhispana?

Possible Side Effects and Safety Information

The official regulatory safety profile for topical Ketoconazol Korhispana primarily documents localized reactions at the site of application. Systemic adverse effects are generally not anticipated due to minimal or non-detectable absorption into the bloodstream.


Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the standard regulatory frequency framework derived from clinical trials and post-marketing surveillance.

Frequency Category Representative Adverse Reactions (Abridged)
Common (occurring in ge 1/100 to <1/10 patients) Skin burning sensation, Application site pruritus (itching), Application site erythema (redness).
Uncommon (occurring in ge 1/1,000 to <1/100 patients) Hypersensitivity, Bullous eruption, Contact dermatitis, Application site irritation, Application site dryness.
Not Known (Post-marketing, cannot be estimated from available data) Anaphylactic reaction, Angioedema (severe swelling), Urticaria (Hives), Alopecia (hair loss).

Safety Considerations and Restrictions

Reactions are classified primarily under the Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions System Organ Classes. The official label notes the existence of rare but clinically significant adverse events classified under Immune System Disorders (Anaphylaxis, Angioedema) documented in post-marketing data.

  • Contraindication: Use is restricted for individuals with a known hypersensitivity to the active substance, ketoconazole, or any of the inactive ingredients (excipients) in the gel formulation.
  • Pediatric Safety: Safety and effectiveness have not been established in the pediatric patient population.
  • Exposure-Related Patterns: Excessive topical application may result in heightened localized effects such as pronounced erythema, swelling, and a burning sensation, which are stated to resolve upon ceasing use.

This structure ensures a standardized communication of risks, focusing the safety understanding on localized skin reactions and severe hypersensitivity events as documented by official government health authorities.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Ketoconazol Korhispana

Overdose Scope

  • Documented overdose presentations: Over-application of the topical product may result in erythema (redness), oedema (swelling), and a burning sensation at the application site.
  • Physiological systems affected (as stated in label): The officially documented effects are localized cutaneous manifestations. Severe systemic effects, such as hepatotoxicity or cardiac issues, are not documented for topical overdose.
  • Dose-related or exposure-related factors (if applicable): Overdose is primarily related to excessive topical application or accidental ingestion of the gel.
  • Population-specific overdose notes (if applicable): No population-specific adjustments or unique considerations for pediatric or geriatric overdose management are explicitly stated in the regulatory overdose sections.
  • Emergency-response statements (as written in official documents): Following accidental ingestion, supportive and symptomatic measures must be employed.
  • When immediate medical help is required (label-derived phrasing only): A health care provider or poison control center must be contacted in the event of accidental ingestion. Emergency services must be contacted immediately if the individual has collapsed or is not breathing.

Overdose Classifications (High-Level)

  • Severity classification (as defined in official documents): Topical overdose symptoms are generally considered reversible upon cessation of use. No official experience of severe systemic overdose is documented for the topical gel.
  • Regulatory basis (EMA / FDA / etc.): Information is based on documentation from regulatory agencies, including the U.S. Food and Drug Administration (FDA) and European Summary of Product Characteristics (SmPC).
  • Overdose-context constraints (as defined in official documents): Official labeling states that no specific antidote is known for the management of ketoconazole overdose.

Resulting Overdose Structure

Official overdose statements:

  • The effects of excessive topical use are generally limited to local reactions like erythema and oedema, which resolve upon discontinuation of treatment.
  • The regulatory labels note that no experience of overdose with the topical gel has been officially documented.
  • In the event of accidental ingestion, symptomatic management and immediate contact with a medical resource are mandated.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the official overdose profile by separating local effects from the risk of ingestion-related systemic exposure. For over-application, the required action is simply stopping the product. The profile mandates seeking urgent help from a poison control center or emergency services only in the instance of accidental ingestion, a scenario that requires the application of regulator-described supportive measures.

Advertisements

Therapeutic Uses of Ketoconazol Korhispana

What Ketoconazol Korhispana treats: main uses and benefits

The therapeutic application of Ketoconazol Korhispana is used primarily in domains involving symptomatic relief from superficial fungal and yeast infections. The medication is indicated for conditions such as seborrheic dermatitis, Tinea corporis (ringworm), Tinea cruris (jock itch), Tinea pedis (Athlete's foot), and Pityriasis versicolor. It is commonly used across conditions presenting with localized discomfort and visible skin changes.


Management of Acute Rashes and Chronic Symptom Patterns

The gel is applied in clinical settings that involve acute or unstable symptom patterns, such as the pronounced itching, redness, and scaling associated with ringworm rashes and chronic symptomatic patterns linked to yeast. It is commonly used to help with symptom clusters that may become intense, such as flaking and irritation, playing a role in managing the discomfort and easing the visual presence of lesions. The product is also relevant for easing challenging symptoms of Pityriasis versicolor.

“The medication provides supportive relief when symptoms interfere with routine activities, contributing to improved day-to-day comfort.”


Quick Fact: Support for Itching and Scaling

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

The use of this topical medicine is contraindicated in any individual who has a known hypersensitivity or allergy to the active ingredient, ketoconazole, or to any inactive ingredients within the formulation. Regulatory documents confirm eligibility for immunocompetent adults and adolescents aged 12 years and older. Safety and effectiveness have not been established in pediatric patients below the age of 12 years.

Condition-specific Eligibility Rules

The product is officially indicated only for immunocompetent patients. Unlike the oral form, the topical medicine has no specific restrictions listed based on hepatic or renal impairment due to minimal systemic absorption.

Pregnancy and Lactation Eligibility Status

For pregnant women, the medicine is classified as US FDA Pregnancy Category C; use is conditional and must be assessed as beneficial against the potential fetal risk. For nursing mothers, caution is advised as it is unknown if the drug is excreted in human milk following topical application.

Official Eligibility Statements

Official classifications prohibit use based on hypersensitivity, define use as not established for children under 12, and place pregnant and nursing populations in a cautionary/conditional use category. The eligibility profile is structured by these absolute prohibitions, age limitations, and conditional reproductive status guidelines as defined in regulatory labeling.

Advertisements

What should I know about interactions with other medicines?

Due to its application as a topical gel, Ketoconazol Korhispana exhibits minimal to undetectable systemic absorption, meaning that formal pharmacokinetic drug-drug interaction studies examining major enzyme systems like CYP450 are generally not applicable or performed. Regulatory documentation confirms that interactions with most systemic medicinal products are neither expected nor documented, as the active substance does not reach measurable plasma concentrations. This lack of systemic exposure means the extensive list of contraindicated systemic drugs associated with oral ketoconazole is not relevant for the topical form.

Co-Administration Requirements and Topical Restrictions

Interaction information for the gel primarily concerns co-applied topical substances and administrative timing rules, not systemic interaction risk.

  • Topical Corticosteroids: Co-treatment requires the implementation of a management protocol. Prolonged use of topical corticosteroids must be gradually withdrawn when initiating treatment to avoid a potential rebound effect upon cessation. This is an official procedural constraint documented in regulatory labeling.
  • Timing of Co-Applied Products: To ensure optimal efficacy, the regulatory label specifies timing separation requirements for non-medicinal products applied to the treatment area. Cosmetics and sunscreens must not be applied until at least 20 minutes after the medicine has been used.
  • Topical Powders: The administration of bland, absorbent powders is advised to be used between the times the antifungal medicine is applied, rather than concurrently.
Advertisements

Mechanism of Action

Modulation of Fungal Cell Membrane Synthesis

Ketoconazole acts within domains involving cytochrome P450-dependent enzyme signaling, specifically by inhibiting fungal lanosterol 14alpha-demethylase. This modifies the early molecular step of ergosterol biosynthesis, an essential component of the fungal cell membrane. The inhibition of this enzyme alters the subsequent sterol pathway activity, resulting in predictable physiological adjustments that alters the phospholipid and sterol composition of the fungal cell membrane.


Influence on Vertebrate Steroidogenesis Pathways

The drug also engages mechanisms that regulate other cytochrome P450 enzymes found in vertebrate systems, which are essential for steroid hormone synthesis. This off-target effect initiates a signaling sequence that suppresses the production of adrenal and gonadal steroids like cortisol and testosterone, thereby modifying the concentration of endogenous steroid hormones by inhibiting P450 enzymes involved in their synthesis.

Advertisements

Dosage and Administration Information

How to Use Ketoconazol Korhispana

Ketoconazol Korhispana 2% Gel is an antifungal medicine formulated solely for topical administration to the skin. The official instructions for its use define a standardized regimen that governs the administration route, frequency, and duration of the course.


Official Administration Guidelines

Administration Scope Specification
Route of Administration Topical (Cutaneous) Use Only. Not approved for oral, ophthalmic, or intravaginal administration.
Dosing Schedule Apply once daily to the affected skin area.
Treatment Duration The standard course for seborrheic dermatitis is typically two weeks.

Procedural Structure and Constraints

The established protocol directs users to apply a sufficient amount of the Gel and gently massage it into the affected area of the skin. Application must be performed with care to avoid contact with mucous membranes, such as the eyes or mouth. Should accidental contact occur, the affected area is generally instructed to be rinsed with water.

The official guidelines establish age restrictions for administration. The 2% Gel is indicated for use in patients 12 years of age and older. The safety and effectiveness of the Gel have not been formally established for use in children younger than 12 years.

Additionally, due to the nature of the formulation, the Gel is formally recognized as flammable. Consequently, official use protocols require the user to avoid exposure to fire, flame, or smoking during and immediately following the application process.

If no clinical improvement is observed after the specified two-week duration, the official documentation stipulates that the diagnosis should be re-evaluated.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Ketoconazol Korhispana

This section provides an overview of the research and clinical studies conducted on topical ketoconazole. It is important to remember that study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes. Research provides context but not individual predictions, and contributes to the broader evidence landscape for this topical medicine.

Evidence for use in Seborrheic Dermatitis

The research exploring Seborrheic Dermatitis includes short-term, double-blind Randomized Controlled Trials (RCTs), with subsequent findings incorporated into systematic reviews and meta-analyses. These trials were typically conducted during periods of increased symptom activity and compared the topical preparation against a non-active vehicle (placebo) or against other active treatment formulations.

Research examined outcomes linked to inflammatory or irritative states such as erythema (redness) and scaling (flaking), in addition to monitoring patient-reported outcomes describing perceived discomfort, specifically pruritus (itching) severity. Studies focused on adults and adolescents (ge 12 years) presenting with this condition. Findings describe patterns observed in the studies related to the evolution of specific visible signs. Evidence quality varies across studies due to differences in design and the specific type of topical product used.

Evidence for use in Superficial Tinea Infections

Topical ketoconazole was studied for Tinea infections, including Tinea pedis, Tinea cruris, and Tinea corporis. These studies were typically double-blind controlled trials that focused on adults and older adults with infections confirmed by laboratory tests. Research examined two main outcome areas: clinical outcomes (assessment of specific visible signs such as scaling and fissuring) and mycological outcomes (laboratory test results documenting fungal presence or absence).

Findings describe group patterns related to measured clinical and mycological outcomes. However, the majority of dedicated trials focused specifically on Tinea pedis, and comparative evidence for other Tinea types remains insufficient.

Key Uncertainties and Research Gaps

As follow-up durations were limited, long-term effects are not fully established, particularly regarding the monitoring of symptoms over many months or years. Comprehensive patient-reported outcomes describing perceived discomfort were not uniformly measured across all pivotal studies, leaving a gap in understanding the impact on daily life. Data for children younger than 12 years of age remains insufficient, as safety and effectiveness are not fully established in this group.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ketoconazol Korhispana (FAQ)


Q: Is Ketoconazol Korhispana used for viral or bacterial infections, or only fungal ones?

Ketoconazol Korhispana is classified as an azole antifungal medicine. This product is indicated for the management of infections caused by specific pathogenic fungi and yeasts. Regulatory information confirms that this product is not effective against infections caused by bacteria or viruses.


Q: Does Ketoconazol Korhispana work on all types of yeast infections?

Official product information confirms that Ketoconazole works by altering the cell membrane of specific fungi and yeasts, which limits their growth. The medication is shown to be effective against a defined spectrum of common dermatophytes and yeasts. Official documentation contains a list of the organisms for which the product is indicated.


Q: Can Ketoconazol Korhispana be used to treat infections on any part of the body?

Ketoconazol Korhispana is formulated for topical use, meaning it is restricted to application on the skin. Regulatory guidelines caution users to avoid applying the medicine to areas with cuts, scrapes, or burns. The medication is also contraindicated for contact with mucous membranes, such as the eyes, nose, or mouth.


Q: How often is Ketoconazol Korhispana shampoo generally used to prevent the recurrence of dandruff?

The official usage guidelines define a specific, variable dosing schedule for controlling symptoms during the initial phase of treatment. A separate schedule is also defined for prophylactic use to help prevent recurrence. Patients should refer to the product label for the full, detailed regimen.


Q: Is it safe to use Ketoconazol Korhispana after its expiration date?

Regulatory guidance specifies that any medication that has passed its expiration date is to be properly discarded. The safety, quality, and full effectiveness of the product cannot be assured once the labeled expiration date is reached.


Q: What are the signs of a serious allergic reaction to Ketoconazol Korhispana?

Official safety information advises that signs of a serious allergic reaction may include a skin rash, itching, or hives. Severe reactions are described as involving swelling of the face, lips, tongue, or throat.


Q: What is known about the possibility of adrenal gland problems linked to Ketoconazol Korhispana?

The topical forms of this medicine, such as the cream, gel, or shampoo, are generally not absorbed into the bloodstream in measurable amounts. For this reason, official safety information indicates that the topical forms have not been associated with adrenal gland problems, which is a known concern with the oral tablets.


Q: What non-drug products (like certain soaps or clothing) might affect the treatment outcome?

The official product information mentions specific precautions regarding clothing during treatment. For instance, the labeling suggests clean, cotton socks and well-ventilated shoes for athlete's foot. For jock itch, the guidance includes wearing loose-fitting, cotton underwear and avoiding synthetic materials like wool, rayon, or nylon.


Q: Is Ketoconazol Korhispana considered a steroid medicine?

Ketoconazol Korhispana is a synthetic broad-spectrum antifungal agent belonging to the azole pharmacological class. Regulatory information classifies it as an antifungal medicine, not a steroid.


Q: Is there a difference in purpose between the Ketoconazol Korhispana cream and shampoo forms?

Yes, the specific indications can differ based on the formulation. The cream or gel is indicated for various Tinea infections and seborrheic dermatitis. The shampoo formulation is commonly indicated for seborrheic dermatitis (dandruff) and tinea versicolor.


Q: Is Ketoconazol Korhispana available in different strengths or concentrations?

Regulatory documentation indicates that the topical formulation is most commonly available as 2% strength in various forms, including cream, gel, and shampoo. Additionally, a 1% shampoo is available for over-the-counter use.


Q: How quickly do people typically see an improvement when using Ketoconazol Korhispana cream or shampoo?

According to official clinical information, patients may see evidence of clinical improvement fairly soon after beginning treatment. However, the full treatment course duration is significantly longer and is determined by the specific condition being treated.


Q: Is it normal for symptoms to return after stopping the use of Ketoconazol Korhispana?

If the full treatment course is not completed, there is a possibility that the underlying infection may not be fully cured. Regulatory information indicates that this can result in the return of symptoms shortly after the medication is stopped.


Q: What happens if someone stops using the medication before the full treatment time is complete?

Stopping the treatment before the full duration is completed may mean the infection is not completely resolved. Regulatory information states that if this happens, the symptoms may return shortly after the medication is ceased.


Q: What are the general expectations for a patient using Ketoconazol Korhispana for a long period of time?

Official data includes results from long-term animal studies assessing the potential for carcinogenic activity (causing cancer). These studies did not show any evidence of oncogenic activity linked to the medication.


Q: Does treatment duration vary depending on the specific condition being treated?

Yes, the required treatment time varies depending on the specific type of fungal infection being addressed. For example, the treatment duration for tinea pedis (athlete’s foot) is generally longer than the duration required for conditions like tinea corporis or tinea cruris.


Q: Are there any known effects of Ketoconazol Korhispana shampoo on hair color or texture, such as curl removal?

Official patient information notes that reports have been made regarding changes to hair color and abnormal hair texture. This includes reports of the curl being removed from hair that has been permanently waved.


Q: Can Ketoconazol Korhispana make the treated skin area more sensitive to sunlight?

Studies conducted on the topical gel formulation have examined its potential to cause photosensitivity (reaction to light). Official information indicates that the gel formulation is not considered photocarcinogenic when applied topically.


Q: Is there a concern about using Ketoconazol Korhispana on broken or damaged skin?

Regulatory guidelines specify that the product is contraindicated for use on skin areas that are broken, cut, scraped, or burned. This precaution is noted due to concerns about irritation and potential systemic exposure.


Q: How should a missed application of Ketoconazol Korhispana be handled?

Official usage guidance provides specific instructions for managing a missed application. Instructions are provided to ensure the subsequent application is not doubled, and patients should refer to the product label for the exact regimen.


Q: Why is it important to wash hands before and after using the topical medication?

Regulatory and medical guidance emphasizes that washing hands before and after use is an important step. This procedure helps to prevent the active infection from being spread to other parts of the body or to other people.


Q: Can the foam form of Ketoconazol Korhispana be applied directly to the hands?

The administration instructions for the foam formulation specify that the product should first be sprayed into the container cap or onto a cool surface. Applying it directly to the hand may cause the foam to melt before the medication can be properly applied.


Q: Can Ketoconazol Korhispana remove the curl from chemically-treated hair?

Official patient information notes that reports have indicated the removal of the curl from hair that has been permanently waved.


Q: What is the purpose of continuing to use the cream for a few days after the infection appears clear?

Regulatory guidance often advises continuing the application for a short period, such as a few days, after the symptoms have visibly cleared up. This continued use helps ensure the infection is completely eliminated and reduces the chance of recurrence.

Advertisements

How should Ketoconazol Korhispana be stored and disposed of?

Storage and Disposal of Ketoconazol Korhispana (Ketoconazole 2% Gel)

Official regulatory documents define specific requirements for the storage, handling, and disposal of ketoconazole 2% gel.

Storage Conditions

Requirement Specification
Storage Temperature Store at 25^circC (77^circF); excursions permitted to 15^circC to 30^circC (59^circF to 86^circF).
Prohibited Conditions Do not freeze or refrigerate. Protect from excess heat, moisture, and direct light.
Handling Precaution The contents are flammable. Avoid use near fire, flame, or smoking during and immediately after application.
Container Rule Keep the medication in the original container, tightly closed.

Safety and Disposal

The product must be kept out of the sight and reach of children. Unused or expired medication should be discarded according to professional guidance; consult a pharmacist or healthcare provider for proper disposal procedures. Do not flush the product down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ketoconazol Korhispana found in:

A-Z Index: